Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

133.15USD
16 Feb 2018
Change (% chg)

$1.92 (+1.46%)
Prev Close
$131.23
Open
$130.88
Day's High
$134.43
Day's Low
$130.88
Volume
2,799,882
Avg. Vol
2,190,455
52-wk High
$148.32
52-wk Low
$117.00

Select another date:

Thu, Feb 15 2018

Photo

FDA approves J&J prostate cancer treatment

The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

UPDATE 2-FDA approves J&J prostate cancer treatment

Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada for use in prostate cancer patients whose disease has not spread but continues to grow despite hormone therapy.

FDA approves J&J prostate cancer treatment

Feb 14 The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's Erleada treatment for use with prostate cancer patients whose cancer has not spread but continues to grow despite hormone therapy.

J&J takes $13.6 billion charge related to new U.S. tax law

Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.

U.S. appeals court upholds ruling invalidating J&J patent on Remicade

A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

US STOCKS-S&P, Nasdaq get Netflix boost; Dow dragged by J&J, Procter

* Dow down 0.07 pct, S&P 500 up 0.15 pct, Nasdaq up 0.56 pct (Updates to mid-afternoon, changes byline)

U.S. appeals court upholds ruling invalidating J&J patent on Remicade

A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

UPDATE 2-U.S. appeals court upholds ruling invalidating J&J patent on Remicade

Jan 23 A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug Remicade, limiting J&J’s ability to seek damages from Pfizer Inc over its launch of a lower-cost version of the drug.

J&J takes $13.6 billion charge related to new U.S. tax law

Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.

UPDATE 4-J&J takes $13.6 bln charge related to new U.S. tax law

Jan 23 Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.

Select another date: